Plasma metabolomics reveals N-arachidonylglycine as a potential biomarker in acute coronary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20241206002

Enrollment

Registered

2024-12-06

Start date

2022-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Untargeted metabolomics analysis in acute coronary syndrome patients Metabolomics Acute coronary syndrome

Interventions

Patients with acute coronary syndrome are confirmed based on clinical presentation, electrocardiographic findings, cardiac enzyme, and confirmatory coronary angiography. ,Healthy patients with no unde

Diagnostic,Diagnostic

Acute coronary syndrome patients,Healthy

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Acute coronary syndrome patients 2. Healthy patients

Exclusion criteria

Exclusion criteria: 1. Severe kidney impairment,an estimated GFR of <30, 2. Severe liver disease with AST or ALT levels more than five times the upper normal limit, 3. Cardiogenic shock

Design outcomes

Primary

Measure	Time frame
metabolite changes in plasma samples from patients with ACS through untargeted liquid chromatography-mass spectrometry (LCMS) metabolomics profiling analysis 10 months Partial Least Squares Discriminant Analysis (PLS-DA)	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public Contactviroj muangsillapasart

Chulabhorn hospital

viroj.muang@gmail.com0863304287

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026